C12R 2001/725
Candida albicans
C12R2001/725 (Candida albicans) appears on 7 US grants and 8 published applications in this corpus.
Search patents in C12R- Granted patents
- 7
- Published applications
- 8
- Assignees
- 12
- Inventors
- 27
- Latest grant
- 30 Sep 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1979 | 1 | 0 |
| 1980 | 1 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 1 | 0 |
| 2003 | 0 | 1 |
| 2004 | 1 | 1 |
| 2005 | 0 | 1 |
| 2006 | 1 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 1 |
| 2022 | 0 | 0 |
| 2023 | 0 | 1 |
| 2024 | 0 | 1 |
| 2025 | 1 | 0 |
| 2026 | 0 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Fecal fungome and therapeutic efficacy of fecal microbiota transplantation30 Sep 2025US 12,427,175 B2The Chinese University of Hong Kong
- Antigenic preparations15 Aug 2006US 7,090,857 B2Boehringer Ingelheim Vetmedica GmbH
- Gene disruption methodologies for drug target discovery31 Aug 2004US 6,783,985 B1Elitra Pharmaceuticals, Inc.
- Antigenic preparations30 Apr 2002US 6,379,678 B1Boehringer Indgelheim Vetmedica GmbH
- Mycosis vaccines18 Sep 2001US 6,290,950 B1
- Method for producing long-chain dicarboxylic acid and long-chain dicarboxylic acid8 Oct 2026US 2026/0308646 A1Cathay Biotech Inc.
- Improved microbial growth media6 Aug 2026US 2026/0226402 A1Becton, Dickinson and Company
- Antibodies against candida albicans proteins and their therapeutic and prophylactic use for treating and preventing invasive fungal infections24 Oct 2024US 2024/0352099 A1
- Fecal fungome and therapeutic efficacy of fecal microbiota transplantation12 Oct 2023US 2023/0321166 A1The Chinese University of Hong Kong
- Fecal fungome and therapeutic efficacy of fecal microbiota transplantation11 Feb 2021US 2021/0038663 A1The Chinese University of Hong Kong
Most cited
By later US patents
- Gene disruption methodologies for drug target discovery9US 6,783,985 B1Elitra Pharmaceuticals, Inc. · 2004
- Sarcoma 180 tumor inhibitor and method of making same7US 4,182,753 A1980
- Fungal growth media6US 4,144,133 AJ. K. and Susie L. Wadley Research Institute and Blood Bank · 1979
- Mycosis vaccines5US 6,290,950 B12001
- Antigenic preparations2US 6,379,678 B1Boehringer Indgelheim Vetmedica GmbH · 2002